Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

No Hat Trick For Roche's Gazyva In Lymphoma

Executive Summary

Roche's Gazyva/Gazyvaro missed its primary endpoint in a Phase III study in first-line diffuse large B-cell lymphoma, failing to score a treble in lymphoma indications for the product, which the company is relying on to replace revenues from the increasingly biosimilared rituximab. The failure has also brought to investors' minds the larger uncertainty over Perjeta's future in breast cancer in the APHINITY study.


Related Content

Gazyva’s GALLIUM Could Be ‘Practice-Changing’ For Follicular Lymphoma
ASH 2016 Preview: Don't Miss These 10 Data Presentations
Spate Of Late-Stage DLBCL Trial Failures Leaves Spoils Waiting
New Market For Genentech's Gazyva: Follicular Lymphoma


Related Companies